Pathogenesis of sepsis and sepsis-induced acute lung injury

Acute Respiratory Distress Syndrome, Second Edition

Volumn , Issue , 2016, Pages 369-419

  Harris, Estelle S ^a   Rondina, Matthew T ^a   Schwertz, Hansjörg ^a   Weyrich, Andrew S ^a   Zimmerman, Guy A ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85052163445     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (357)

1. Beutler B. Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002; 9(1):2-10.
2. Ashbaugh, DG, Bigelow DB, et al. Acute respiratory distress in adults. Lancet 1967; 2(7511):319-323.
3. Kaplan RL, Sahn SA, et al. Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. Arch Intern Med 1979; 139(8):867-869.
4. Bernard GR, Artigas A, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149(3, pt 1):818-824.
5. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342(18):1334-1349.
6. MatthayMA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005; 33(4):319-327.
7. Ware LB. Pathophysiology of acute lung injury and the acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27(4):337-349.
8. Leaver SK, Evans TW. Acute respiratory distress syndrome. BMJ 2007; 335(7616):389-394.
9. Zimmerman GA, Albertine KH, et al. Pathogenesis of sepsis and septic-induced lung injury. In:Matthay MA, ed. AcuteRespiratory Distress Syndrome, vol. 179. NewYork/Basel: Marcel Dekker, Inc., 2003:245-287.
10. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3(2):169-176.
11. Parsons PE, Worthen GS, et al. The association of circulating endotoxin with the development of the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 140(2):294-301.
12. Pittet JF, Mackersie RC, et al. Biological markers of acute lung injury: prognostic and pathogenetic significance. Am J Respir Crit Care Med 1997; 155(4):1187-1205.
13. Pepe PE, Potkin RT, et al. Clinical predictors of the adult respiratory distress syndrome. Am J Surg 1982; 144(1):124-130.
14. Hudson LD, Milberg JA, et al. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med 1995; 151(2, pt 1):293-301.
15. Rangel-Frausto MS. The epidemiology of bacterial sepsis. Infect Dis Clin North Am 1999; 13(2):299-312, vii.
16. Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29(7):1303-1310.
17. Vincent JL, Abraham E. The last 100 years of sepsis. Am J Respir Crit Care Med 2006; 173(3):256-263.
18. Liu KD, Levitt J, et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008; 178(6): 618-623.
19. Annane D, Sebille V, et al. Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med 2006; 34(1): 22-30.
20. Stoll BJ, Hansen RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002-2003. Pediatr Infect Dis J 2005; 24:635-639.
21. Nadel S, Goldstein B, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369(9564):836-843.
22. Wong HR, Cvijanovich N, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178(3):276-282.
23. Martin GS, Mannino DM, et al. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34(1):15-21.
24. Gomez CR, Hirano S, Cutro BT, et al. Advanced age exacerbates the pulmonary inflammatory response after lipopolysaccharide exposure. Crit Care Med 2007; 35(1):246-251.
25. Riedemann NC, Guo RF, et al. Novel strategies for the treatment of sepsis. Nat Med 2003; 9(5):517-524.
26. Bucala R. Series introduction: molecular and cellular basis of septic shock. J Leukoc Biol 2004; 75(3):398-399.
27. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005; 56:225-248.
28. Baron RM, Baron MJ, et al. Pathobiology of sepsis: are we still asking the same questions? Am J Respir Cell Mol Biol 2006; 34(2):129-134.
29. Munford RS. Severe sepsis and septic shock: the role of gram-negative bacteremia. Annu Rev Pathol 2006; 1:467-496.
30. Russell JA. Management of sepsis. N Engl J Med 2006; 355(16):1699-1713.
31. Annane D, Bellissant E, et al. Septic shock. Lancet 2005; 365(9453):63-78.
32. Alberti C, Brun-Buisson C, Chevret S, et al. Systemic inflammatory response and progression to severe sepsis in critically ill infected patients. Am J Respir Crit Care Med 2005; 171:461-468.
33. Ulloa L, Tracey KJ. The cytokine profile: a code for sepsis. Trends Mol Med 2005; 11(2):56-63.
34. Laterre PF, Garber G, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33(5):952-961.
35. Kellum JA, Kong L, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med 2007; 167(15):1655-1663.
36. Annane D, Aegerter P, et al. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003; 168(2):165-172.
37. Bastarache JA, Ware LB, et al. The role of the coagulation cascade in the continuum of sepsis and acute lung injury and acute respiratory distress syndrome. Semin Respir Crit Care Med 2006; 27(4):365-376.
38. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20(6):864-874.
39. Abraham E. Matthay MA, et al. Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med 2000; 28(1):232-235.
40. Levy MM, Fink MP, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31(4):1250-1256.
41. Wang H, Czura CJ, et al. Lipid unites disparate syndromes of sepsis. Nat Med 2004; 10(2):124-125.
42. Stüber F. Human responses to endotoxin: role of the genetic background. In: Brade H, Opal SM, Vogel SN, et al., eds. Endotoxin in Health and Disease. New York: Marcel Dekker, Inc., 1999:877-885.
43. Cariou A, Chiche JD, et al. The era of genomics: impact on sepsis clinical trial design. Crit Care Med 2002; 30(Suppl. 5):S341-S348.
44. Barnes KC. Genetic determinants and ethnic disparities in sepsis-associated acute lung injury. Proc Am Thorac Soc 2005; 2(3):195-201.
45. Opal SM, Cross AS. Clinical trials for severe sepsis. Past failures, and future hopes. Infect Dis Clin North Am 1999; 13(2):285-297, vii.
46. Marshall JC. Such stuffas dreams are made on: mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2(5):391-405.
47. Huston JM, Ochani M, Rosas-Ballina M, et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006; 203(7):1623-1628.
48. Kerfoot SM, Kubes P. Local coordination verses systemic disregulation: complexities in leukocyte recruitment revealed by local and systemic activation of TLR4 in vivo. J Leukoc Biol 2005; 77(6):862-867.
49. Esmon CT. Sepsis. A myriad of responses. Lancet 2001; 358(Suppl.):S61.
50. Cohen J. The immunopathogenesis of sepsis. Nature 2002; 420(6917):885-891.
51. Nathan C. Points of control in inflammation. Nature 2002; 420(6917):846-852.
52. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships between coagulation and the innate immune response and their respective roles in the pathogenesis of sepsis. Crit Care 2003; 7(1):23-38.
53. Bateman RM, Sharpe MD, et al. Bench-to-bedside review: microvascular dysfunction in sepsis-hemodynamics, oxygen transport, and nitric oxide. Crit Care 2003; 7(5):359-373.
54. Schouten M, Wiersinga WJ, et al. Inflammation, endothelium, and coagulation in sepsis. J Leukoc Biol 2008; 83(3):536-545.
55. Haden DW, Suliman HB, Carraway MS, et al. Mitochondrial biogenesis restores oxidative metabolism during Staphylococcus aureus sepsis. AmJ Respir Crit Care Med 2007; 176:762-777.
56. d'Avila JC, Santiago AP, Amancio RT, et al. Sepsis induces brain mitochondrial dysfunction. Crit Care Med 2008; 36(6):1925-1932.
57. Singer G, Stokes KY, et al. Sepsis-induced intestinal microvascular and inflammatory responses in obese mice. Shock 2008; 31(3):275-279.
58. Michalek SM, Moore RN, et al. The primary role of lymphoreticular cells in the mediation of host responses to bacterial endotoxim. J Infect Dis 1980; 141(1):55-63.
59. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6(3):173-182.
60. Lekstrom-Himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000; 343(23):1703-1714.
61. Bunting M, Harris ES, et al. Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving beta 2 integrins and selectin ligands. Curr Opin Hematol 2002; 9(1):30-35.
62. Levin BR, Antia R. Why we don't get sick: the within-host population dynamics of bacterial infections. Science 2001; 292(5519):1112-1115.
63. Beutler B, Poltorak A. Sepsis and evolution of the innate immune response. Crit Care Med 2001; 29(7 Suppl):S2-6; discussion S6-7.
64. Aderem A. Role of Toll-like receptors in inflammatory response in macrophages. Crit Care Med 2001; 29(Suppl. 7):S16-S18.
65. Gordon S. The macrophage: past, present and future. Eur J Immunol 2007; 37(Suppl. 1):S9-S17.
66. Miyazaki Y, Bunting M, Stafforini DM, et al. Integrin alphaDbeta2 is dynamically expressed by inflamed macrophages and alters the natural history of lethal systemic infections. J Immunol 2008; 180(1):590-600.
67. LeeWL, Downey GP. Neutrophil activation and acute lung injury. Curr Opin Crit Care 2001; 7(1):1-7.
68. Abraham E. Neutrophils and acute lung injury. Crit Care Med 2003; 31(Suppl. 4):S195-S199.
69. Rodrigues RS, Zimmerman GA. Pulmonary endothelial interactions with leukocytes and platelets. In: Rounds A, Voelkel N, eds. The Pulmonary Endothelium. London, UK: John Wiley and Sons, Ltd, 2008.
70. Ibbotson GC, Doig C, Kaur J, et al. Functional alpha4-integrin: a newly identified pathway of neutrophil recruitment in critically ill septic patients. Nat Med 2001; 7(4):465-470.
71. Docke WD, Randow F, et al. Monocyte deactivation in septic patients: restoration by IFNgamma treatment. Nat Med 1997; 3(6):678-681.
72. Adib-Conquy M, Adrie C, Moine P, et al. NF-kappaB expression in mononuclear cells of patients with sepsis resembles that observed in lipopolysaccharide tolerance. Am J Respir Crit Care Med 2000; 162(5):1877-1883.
73. Fahy RJ, Exline MC, Gavrilin MA, et al. Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 2008; 177(9):983-988.
74. Fingerle G, Pforte A, et al. The novel subset of CD14+/CD16+blood monocytes is expanded in sepsis patients. Blood 1993; 82(10):3170-3176.
75. Belge KU, Dayyani F, Horelt A, et al. The proinflammatory CD14+CD16+DR++monocytes are a major source of TNF. J Immunol 2002; 168(7):3536-3542.
76. Gibot S, Kolopp-Sarda MN, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141(1):9-15.
77. Bohnsack JF, Akiyama SK, et al. Human neutrophil adherence to laminin in vitro. Evidence for a distinct neutrophil integrin receptor for laminin. J Exp Med 1990; 171(4):1221-1237.
78. Guo RF, Riedemann NC, Laudes IJ, et al. Altered neutrophil trafficking during sepsis. J Immunol 2002; 169(1):307-314.
79. Reutershan J, Ley K. Bench-to-bedside review: acute respiratory distress syndrome-how neutrophils migrate into the lung. Crit Care 2004; 8(6):453-461.
80. Mayadas TN, Cullere X. Neutrophil beta2 integrins: moderators of life or death decisions. Trends Immunol 2005; 26(7):388-395.
81. Fialkow L, Filho LF, Bozzetti MC, et al. Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit Care 2006; 10(6):R155.
82. Brinkmann V, Reichard U, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303(5663):1532-1535.
83. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007; 176(2):231-241.
84. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med 2007; 13(4):463-469.
85. Ma AC, Kubes P. Platelets, neutrophils, and neutrophil extracellular traps (NETs) in sepsis. J Thromb Haemost 2008; 6(3):415-420.
86. Flierl MA, Rittirsch D, Nadeau BA, et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 2007; 449(7163):721-725.
87. Wang L, Kamath A, Das H, et al. Antibacterial effect of human V gamma 2V delta 2 T cells in vivo. J Clin Invest 2001; 108(9):1349-1357.
88. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002; 168(5):2493-2500.
89. Oberholzer A, Oberholzer C, Bahjat KS, et al. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J Immunol 2002; 168(7):3412-3418.
90. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348(2):138-150.
91. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161): 419-426.
92. Opal SM, Huber CE. SEPSIS. Sci Am Med 2001; 30:1-17.
93. Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signalling couples coagulation and inflammation. Nature 2008; 452(7187):654-658.
94. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91(10):3527-3561
95. Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003a; 78(7):869-881.
96. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome. Blood 2003b; 101(10):3765-3777.
97. Hack CE, Zeerleder S. The endothelium in sepsis: source of and a target for inflammation. Crit Care Med 2001; 29(Suppl. 7):S21-S27.
98. Martinez ML, Zimmerman GA. Endothelial biomedicine. In: Aird WC, ed. Endothelium Biomedicine. Cambridge: Cambridge University Press, 2007:1178-1192.
99. Reutershan J, Morris MA, Burcin TL, et al. Critical role of endothelial CXCR2 in LPSinduced neutrophil migration into the lung. J Clin Invest 2006; 116(3):695-702.
100. Mutunga M, Fulton B, et al. Circulating endothelial cells in patients with septic shock. Am J Respir Crit Care Med 2001; 163(1):195-200.
101. Neilsen PO, Zimmerman GA, et al. Escherichia coli Braun lipoprotein induces a lipopolysaccharide-like endotoxic response from primary human endothelial cells. J Immunol 2001; 167(9):5231-5239.
102. Henneke P, Golenbock DT. Innate immune recognition of lipopolysaccharide by endothelial cells. Crit Care Med 2002; 30(Suppl. 5):S207-S213.
103. Gill EA, Imaizumi T, et al. Bacterial lipopolysaccharide induces endothelial cells to synthesize a degranulating factor for neutrophils. FASEB J 1998; 12(9):673-684.
104. Zhao B, Bowden RA, et al. Human endothelial cell response to gram-negative lipopolysaccharide assessed with cDNA microarrays. Am J Physiol Cell Physiol 2001; 281(5):C1587-C1595.
105. Turner GD, Ly VC, et al. Systemic endothelial activation occurs in both mild and severe malaria. Correlating dermal microvascular endothelial cell phenotype and soluble cell adhesion molecules with disease severity. Am J Pathol 1998; 152(6):1477-1487.
106. Leone M, Boutiere B, Camoin-Jau L, et al. Systemic endothelial activation is greater in septic than in traumatic-hemorrhagic shock but does not correlate with endothelial activation in skin biopsies. Crit Care Med 2002; 30(4):808-814.
107. Müller AM, Cronen C, Müller KM, et al. Heterogeneous expression of cell adhesion molecules by endothelial cells in ARDS. J Pathol 2002; 198(2):270-275.
108. Ye X, Ding J, Zhou X, et al. Divergent roles of endothelial NF-kappaB inmultiple organ injury and bacterial clearance in mouse models of sepsis. J Exp Med 2008; 205(6):1303-1315.
109. Yano K, Liaw PC, Mullington JM, et al. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006; 203(6): 1447-1458.
110. Weyrich AS, Lindemann S, et al. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1(9):1897-1905.
111. Weyrich AS, Zimmerman GA. Platelets: signaling cells in the immune continuum. Trends Immunol 2004; 25(9):489-495.
112. Vincent JL, Yagushi A, et al. Platelet function in sepsis. Crit Care Med 2002; 30(Suppl. 5):S313-S317.
113. Warkentin TE, Aird WC, et al. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2003; 2003(1):497-519.
114. Schwertz H, Weyrich AS, et al. Interacoes entre plaquetas, leucocitos e endothelia na resposta inflamatoria sistemica e na sepse (Cellular interactions of platelets, leukocytes and endothelium in systemic inflammatory responses and sepsis). In: Caire de Castro FNH, Marcus David C, eds. Sepse: Da Bancada a Beira Do Leto. Rio de Janerio: Revinter Press, 2007:107-120.
115. Bozza FA, Shah AM, Weyrich AS, et al. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2008; 40(2):123-134.
116. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost 2004; 91(2):213-224.
117. Levi M. Platelets at a crossroad of pathogenic pathways in sepsis. J Thromb Haemost 2004; 2(12): 2094-2095.
118. Zeerleder S, Hack CE, et al. Disseminated intravascular coagulation in sepsis. Chest 2005; 128(4):2864-2875.
119. Croner RS, Hoerer E, et al. Hepatic platelet and leukocyte adherence during endotoxemia. Crit Care 2006; 10(1):R15.
120. Grewal PK, Uchiyama S, Ditto D, et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008; 14(6):648-655.
121. Yaguchi A, Lobo FL, et al. Platelet function in sepsis. J Thromb Haemost 2004; 2(12):2096-2102.
122. Evans G, Lewis AF, et al. The role of platelet aggregation in the development of endotoxin shock. Br J Surg 1969; 56(8):624.
123. Cowan DH, Bowman LS, et al. Platelet aggregation as a sign of septicemia in thermal injury. A prospective study. JAMA 1976; 235(12):1230-1234.
124. Gawaz M, Dickfeld T, Bogner C, et al. Platelet function in septic multiple organ dysfunction syndrome. Intensive Care Med 1997; 23(4):379-385.
125. Zimmerman GA, Weyrich AS. Signal-dependent protein synthesis by activated platelets: new pathways to altered phenotype and function. Arterioscler Thromb Vasc Biol 2008; 28(3):s17-24.
126. Weyrich AS, Dixon DA, Pabla R, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci USA 1998; 95(10):5556-5561.
127. Weyrich AS, Schwertz H, Kraiss LW, et al. Protein synthesis by platelets: historical and new perspectives. J Thromb Haemost 2009; 7(2):241-246.
128. Denis MM, Tolley ND, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005; 122(3):379-391.
129. Schwertz H, Tolley ND, et al. Signal-dependent splicing of tissue factor pre-mRNAmodulates the thrombogenicity of human platelets. J Exp Med 2006; 203(11):2433-2440.
130. Ohlsson K, Björk P, Bergenfeldt M, et al. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348(6301):550-552.
131. Pawlinski R, Mackman N. Tissue factor, coagulation proteases, and protease-activated receptors in endotoxemia and sepsis. Crit Care Med 2004; 32(Suppl. 5):S293-S297.
132. Shashkin PN, Brown GT, et al. Lipopolysaccharide is a direct agonist for platelet RNA splicing. J Immunol 2008; 181(5):3495-3502.
133. Rondina M, Schwertz H, Harris E, et al. Manuscript submitted.
134. Zimmerman GA, McIntyre TM, et al. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002; 30(Suppl. 5):S294-S301.
135. Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med 2004; 32(Suppl. 5):S287-S292.
136. Andonegui G, Kerfoot S, McNagny K, et al. Platelets express functional Toll-like receptor-4 (TLR4). Blood 2005; 106(7):2417-2423.
137. Stohlawertz P, Folman CC, et al. Effects of endotoxemia on thrombopoiesis in men. Thromb Haemost 1999; 81:613-617.
138. Zhao L, Ohtaki Y, Yamaguchi K, et al. LPS-induced platelet response and rapid shock in mice: contribution of O-antigen region of LPS and involvement of the lectin pathway of the complement system. Blood 2002; 100(9):3233-3239.
139. Aslam R, Speck ER, Kim M, et al. Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor- production in vivo. Blood 2006; 107(2):637-641.
140. Kiefmann R, Heckel K, et al. Role of p-selectin in platelet sequestration in pulmonary capillaries during endotoxemia. J Vasc Res 2006; 43(5):473-481.
141. Rumbaut RE, Bellera RV, Randhawa JK, et al. Endotoxin enhances microvascular thrombosis in mouse cremaster venules via a TLR4-dependent, neutrophil-independent mechanism. Am J Physiol Heart Circ Physiol 2006; 290(4):H1671-H1679.
142. Kälsch T, Elmas E, Nguyen XD, et al. Endotoxin-induced effects on platelets and monocytes in an in vivo model of inflammation. Basic Res Cardiol 2007; 102(5):460-466.
143. Harlan JM, Winn RK. Leukocyte-endothelial interactions: clinical trials of anti-adhesion therapy. Crit Care Med 2002; 30(Suppl. 5):S214-S219.
144. McIntyre TM, Prescott SM, et al. Cell-cell interactions: leukocyte-endothelial interactions. Curr Opin Hematol 2003; 10(2):150-158.
145. Bergmeier W, Wagner DD. Inflammation. In: Michaelson AD, ed. Platelets. Boston, MA: Academic Press, 2007:713-726.
146. Michaelson M. A model of extraordinary social engagement, or "moral giftedness. New Dir Child Adolesc Dev 2001; (93):19-32.
147. Ma N, Hunt NH, et al. Correlation between enhanced vascular permeability, up-regulation of cellular adhesion molecules and monocyte adhesion to the endothelium in the retina during the development of fatal murine cerebral malaria. Am J Pathol 1996; 149(5):1745-1762.
148. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105(18):2130-2132.
149. Brambilla M, Camera M, Colnago D, et al. Tissue factor in patients with acute coronary syndromes: expression in platelets, leukocytes, and platelet-leukocyte aggregates. Aterioscler Thromb Vasc Biol 2008; 28(5):947-953.
150. Li N, Soop A, et al. Multi-cellular activation in vivo by endotoxin in humans-limited protection by adenosine infusion. Thromb Haemost 2000; 84(3):381-387.
151. Kirschenbaum LA, Aziz M, et al. Influence of rheologic changes and platelet-neutrophil interactions on cell filtration in sepsis. Am J Respir Crit Care Med 2000; 161(5):1602-1607.
152. Ogura H, Kawasaki T, et al. Activated platelets enhance microparticle formation and plateletleukocyte interaction in severe trauma and sepsis. J Trauma 2001; 50(5):801-809.
153. Russwurm S, Vickers J, et al. Platelet and leukocyte activation correlate with the severity of septic organ dysfunction. Shock 2002; 17(4):263-268.
154. Peters MJ, Heyderman RS, Faust S, et al. Severe meningococcal disease is characterized by early neutrophil but not platelet activation and increased formation and consumption of platelet-neutrophil complexes. J Leukoc Biol 2003; 73(6):722-730.
155. SorianoAO, JyW, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med 2005; 33(11):2540-2546.
156. Mirlashari MR, Hagberg IA, et al. Platelet-platelet and platelet-leukocyte interactions induced by outer membrane vesicles from N. meningitidis. Platelets 2002; 13(2):91-99.
157. Bryant AE, Chen RY, et al. Clostridial gas gangrene. I. Cellular and molecular mechanisms of microvascular dysfunction induced by exotoxins of Clostridium perfringens. J Infect Dis 2000; 182(3):799-807.
158. Bryant AE, Bayer CR, Chen RY, et al. Vascular dysfunction and ischemic destruction of tissue in Streptococcus pyogenes infection: the role of streptolysin O-induced platelet/neutrophil complexes. J Infect Dis 2005; 192(6):1014-1022.
159. Bryant AE, Bayer CR, Aldape MJ, et al. Clostridium perfringens phospholipase C-induced platelet/leukocyte interactions impede neutrophil diapedesis. JMed Microbiol 2006; 55(Pt 5): 495-504.
160. GawazM, Fateh-Moghadam S, PilzG, et al. Platelet activation and interactionwith leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995; 25(11):843-851.
161. Heffner JE. Platelet-neutrophil interactions in sepsis-platelet guilt by association? Intensive Care Med 1997; 23(4):366-368.
162. Weyrich AS, McIntyre TM, McEver RP, et al. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest 1995; 95(5):2297-2303.
163. Weyrich AS, Elstad MR, McEver RP, et al. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97(6):1525-1534.
164. Dixon DA, Tolley ND, Bemis-Standoli K, et al. Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling. J Clin Invest 2006; 116(10):2727-2738.
165. Zarbock A, Singbartl K, Ley K. Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest 2006; 116(12):3211-3219.
166. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124(4):783-801.
167. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007; 449(7164):819-826.
168. Medzhitov R, Janeway CA. Decoding the patterns of self and nonself by the innate immune system. Science 2002; 296(5566):298-300.
169. Brunn GJ, Platt JL. The etiology of sepsis: turned inside out. Trends Mol Med 2006; 12(1):10-16.
170. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81(1):1-5.
171. Miyake K. Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007; 19(1):3-10.
172. Barton GM. A calculated response: control of inflammation by the innate immune system. J Clin Invest 2008; 118(2):413-420.
173. Fitzgerald KA, Golenbock DT. Immunology. The shape of things to come. Science 2007; 316(5831):1574-1576.
174. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388(6640):394-397.
175. Rock FL, Hardiman G, et al. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998; 95(2): 588-593.
176. Cook DN, Pisetsky DS, et al. Toll-like receptors in the pathogenesis of human disease. Nat Immunol 2004; 5(10):975-979.
177. Decker T. Sepsis: avoiding its deadly toll. J Clin Invest 2004; 113(10):1387-1389.
178. Beutler B, Jiang Z, et al. Genetic analysis of host resistance: toll-like receptor signaling and immunity at large. Annu Rev Immunol 2006; 24:353-389.
179. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168(2):554-561.
180. Elson G, Dunn-Siegrist I, et al. Contribution of Toll-like receptors to the innate immune response to Gram-negative and Gram-positive bacteria. Blood 2007; 109(4):1574-1583.
181. Plitas G, Burt BM, et al. Toll-like receptor 9 inhibition reduces mortality in polymicrobial sepsis. J Exp Med 2008; 205(6):1277-1283.
182. Kanzler H, Barrat FJ, Hessel EM, et al. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med 2007; 13(5)552-559.
183. Arbour NC, Lorenz E, Schutte BC, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25(2):187-191.
184. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007; 7(3):179-190.
185. Spiller S, Elson G, Ferstl R, et al. LTR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice. J Exp Med 2008; 205(8)1747-1754.
186. Ozinsky A, Underhill MD, Fontenot JD, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci USA 2000; 97(25):13766-13771.
187. Knapp S, von Aulock S, et al. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol 2008; 180(5):3478-3484.
188. Ulevitch RJ. New therapeutic targets revealed through investigations of innate immunity. Crit Care Med 2001; 29(Suppl. 7):S8-S12.
189. Kitchens RL, Thompson PA, et al. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001; 108(3):485-493.
190. Zhang G, Ghosh S. Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity. J Clin Invest 2001; 107(1):13-19.
191. Martin TR. Recognition of bacterial endotoxin in the lungs. Am J Respir Cell Mol Biol 2000; 23(2):128-132.
192. Blackwell TS, Christman JW. Defining the lung's response to endotoxin. Am J Respir Crit Care Med 2001; 163(7):1516-1517.
193. O'Grady NP, Preas HL, et al. Local inflammatory responses following bronchial endotoxin instillation in humans. Am J Respir Crit Care Med 2001; 163(7):1591-1598.
194. Jeyaseelan S, Chu HW, Young SK, et al. Transcriptional profiling of lipopolysaccharideinduced acute lung injury. Infect Immun 2004; 72(12):7247-7256.
195. Abraham E. Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc 2005; 2(3):243-247.
196. Menezes SL, Bozza PT, et al. Pulmonary and extrapulmonary acute lung injury: inflammatory and ultrastructural analyses. J Appl Physiol 2005; 98(5):1777-1783.
197. Knapp S, Florquin S, Golenbock DT, et al. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol 2006; 176(5):3189-3195.
198. Togbe D, Schnyder-Candrian S, Schnyder B, et al. Toll-like receptor and tumour necrosis factor dependent endotoxin-induced acute lung injury. Int J Exp Path 2007; 88(6):387-391.
199. Hoogerwerf JJ, de Vos AF, et al. Lung inflammation induced by lipoteichoic acid or lipopolysaccharide in humans. Am J Respir Crit Care Med 2008; 178(1):34-41.
200. Held HD, Boettcher S, et al. Ventilation-induced chemokine and cytokine release is associated with activation of nuclear factor-kappaB and is blocked by steroids. Am J Respir Crit Care Med 2001; 163(3, pt 1):711-716.
201. Andonegui G, Bonder CS, Green F, et al. Endothelium-derived Toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs. J Clin Invest 2003; 111(7):1011-1020.
202. Togbe D, Schnyder-Candrian S, Schnyder B, et al. TLR4 gene dosage contributes to endotoxin-induced acute respiratory inflammation. J Leukoc Biol 2006; 80(3):451-457.
203. Tasaka S, Ishizaka A, et al. Effect of CD14 blockade on endotoxin-induced acute lung injury in mice. Am J Respir Cell Mol Biol 2003; 29(2):252-258.
204. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 2005; 436(7047):112-116.
205. Didierlaurent A, Goulding J, Patel S, et al. Sustained desensitization to bacterial Tolllike receptor ligands after resolution of respiratory influenza infection. J Exp Med 2008; 205(2):323-329.
206. Meylan E, Tschopp J, et al. Intracellular pattern recognition receptors in the host response. Nature 2006; 442(7098):39-44.
207. Imaizumi T, Aratani S, et al. Retinoic acid-inducible gene-I is induced in endothelial cells by LPS and regulates expression of COX-2. Biochem Biophys Res Commun 2002; 292(1):274-279.
208. Thimmulappa RK, Lee H, Rangasamy T, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest 2006; 116(4):984-985.
209. Khor CC, Chapman SJ, Vannberg FO, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39(4):523-528.
210. von Bernuth H, Picard C, Jin Z, et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 2008; 321(5889):691-696.
211. van't Veer C, van den Pangaart PS, van Zoelen MA, et al. Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol 2007; 179(10):7110-7120.
212. Faure E, Thomas L, Xu H, et al. Bacterial lipopolysaccharide and IFN-gamma induce Toll-like receptor 2 and Toll-like receptor 4 expression in human endothelial cells: role of NF-kappa B activation. J Immunol 2001; 166(3):2018-2024.
213. Sato S, Sugiyama M, Yamamoto M, et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF) associates with TNF receptor-associated factor 6 and TANKbinding kinase 1, and activates two distinct transcription factors, NF-kappa B and IFNregulatory factor-3, in the Toll-like receptor signaling. J Immunol 2003; 171(8):4304-4310.
214. O'Neill LA. 'Fine tuning' TLR signaling. Nat Immunol 2008; 9(5):459-461.
215. Imai Y, Kuba K, Neely GG, et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133(2):235-249.
216. Suzuki T, Hashimoto S, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000; 96(7):2584-2591.
217. Wang ZM, Liu C, et al. Chemokines are the main proinflammatory mediators in human monocytes activated by Staphylococcus aureus, peptidoglycan, and endotoxin. J Biol Chem 2000; 275(27):20260-20267.
218. Bozza FA, Salluh JI, et al. Cytokine profiles as markers of disease severity in sepsis: a multiplex analysis. Crit Care 2007; 11(2):R49.
219. Maelfait J, Vercammen E, et al. Stimulation of Toll-like receptor 3 and 4 induces interleukin-1beta maturation by caspase-8. J Exp Med 2008; 205(9):1967-1973.
220. Saleh M, Vaillancourt JP, Graham RK, et al. Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms. Nature 2004; 429(6987):75-79.
221. SalehM, Mathison JC, WolinskiMK, et al. Enhanced bacterial clearance and sepsis resistance in caspase-12-deficient mice. Nature 2006; 440(7087):1064-1068.
222. Sarkar A, Hall MW, et al. Caspase-1 regulates Escherichia coli sepsis and splenic B cell apoptosis independently of interleukin-1beta and interleukin-18. Am J Respir Crit Care Med 2006; 174(9):1003-1010.
223. Mastronardi C, Whelan F, Yildiz OA, et al. Caspase 1 deficiency reduces inflammationinduced brain transcription. Proc Natl Acad Sci USA 2007; 104(17):7205-7210.
224. Ware LB, Camerer E, et al. Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006; 291(3):L307-L311.
225. Gomes RN, Figueiredo RT, Bozza FA, et al. Increased susceptibility to septic and endotoxic shock in monocyte chemoattractant protein 1/cc chemokine ligand 2-deficient mice correlates with reduced interleukin 10 and enhanced macrophage migration inhibitory factor production. Shock 2006; 26(25):457-463.
226. Feldmann M, MainiRN. Lasker Clinical Medical ResearchAward. TNFdefined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. Nat Med 2003; 9(10):1245-1250.
227. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173(1):307-313.
228. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279(9):7370-7377.
229. Uchida T, Shirasawa M, Ware LB, et al. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 2006; 173(9): 1008-1015.
230. Tsung A, Klune JR, Zhang X, et al. HMGB1 release induced by liver ischemia involves Toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J Exp Med 2007; 204(12):2913-2923.
231. Qin S, Wang H, Yuan R, et al. Role of HMGB1 in apoptosis-mediated sepsis lethality. J Exp Med 2006; 203(7):1637-1642.
232. Sundéen-Cullberg J, Norrby-Teglund A, Rouhiainen A, et al. Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock. Crit Care Med 2005; 33(3):682-683.
233. Ueno H, Matsuda T, Hashimoto S, et al. Contributions of high mobility group box protein in experimental and clinical acute lung injury. Am J Respir Crit Care Med 2004; 170(12):1310-1316.
234. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101(1):296-301.
235. Abeyama K, Stern DM, Ito Y, et al. The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest 2005; 115(5):1267-1274.
236. Esmon C. Do-all receptor takes on coagulation, inflammation. NatMed 2005; 11(5):475-477.
237. Schofield L. Intravascular infiltrates and organ-specific inflammation in malaria pathogenesis. Immunol Cell Biol 2007; 85(2):130-137.
238. Bozza M, Satoskar AR, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189(2):341-346.
239. Froidevaux C, Roger T, et al. Macrophage migration inhibitory factor and innate immune responses to bacterial infections. Crit Care Med 2001; 29(Suppl. 7):S13-S15.
240. Bozza FA, Gomes RN, et al. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 2004; 22(4):309-313.
241. Donnelly SC, Haslett C, et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 1997; 3(3):320-323.
242. Yan JJ, Jung JS, Lee JE, et al. Therapeutic effects of lysophosphatidylcholine in experimental sepsis. Nat Med 2004; 10(2):161-167.
243. Giebelen IA, Leendertse M, Dessing MC, et al. Endogenous beta-adrenergic receptors inhibit lipopolysaccharide-induced pulmonary cytokine release and coagulation. Am J Respir Cell Mol Biol 2008; 39(3):373-379.
244. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407(6801):258-264.
245. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3(8):1800-1814.
246. Prescott SM, McIntyre TM, et al. Sol Sherry lecture in thrombosis: molecular events in acute inflammation. Arterioscler Thromb Vasc Biol 2002; 22(5):727-733.
247. McIntyre TM, Zimmerman GA, et al. Biologically active oxidized phospholipids. J Biol Chem 1999; 274(36):25189-25192.
248. Prescott SM, Zimmerman GA, et al. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000; 69:419-445.
249. Watanabe J, Marathe GK, Neilsen PO, et al. Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles. J Biol Chem 2003; 278(35):33161-33168.
250. Walton KA, Cole AL, Yeh M, et al. Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler Thromb Vasc Biol 2003; 23(7):1197-1203.
251. Blüml S, Kirchberger S, Bochkov VN, et al. Oxidized phospholipids negatively regulate dendritic cell maturation induced by TLRs and CD40. J Immunol 2005; 175(1):501-508.
252. Nonas S, Miller I, Kawkitinarong K, et al. Oxidized phospholipids reduce vascular leak and inflammation in rat model of acute lung injury. Am J Respir Crit Care Med 2006; 173(10): 1130-1138.
253. Lemjabbar H, Basbaum C. Platelet-activating factor receptor and ADAM10 mediate responses to Staphylococcus aureus in epithelial cells. Nat Med 2002; 8(1):41-46.
254. Han SH, Kim JH, Seo HS, et al. Lipoteichoic acid-induced nitric oxide production depends on the activation of platelet-activating factor receptor and Jak2. J Immunol 2006; 176(1):573-579.
255. Mathiak G, Szewczyk D, et al. Platelet-activating factor (PAF) in experimental and clinical sepsis. Shock 1997; 7(6):391-404.
256. KuijpersTW, van der Poll T. The role of platelet-activating factor in endotoxin-related disease. In: Brade H, Opal SM, Vogel SN, et al., eds. Endotoxin in Health and Disease. New York: Marcel Dekker, 1999:449-462.
257. Yost CC, Denis MM, et al. Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-alpha: a mechanism for translational control of transcriptional events. J Exp Med 2004; 200(5):671-680.
258. Yost CC, Cody MJ, Harris ES, et al. Impaired neutrophil extracellular trap (NET) formation: a novel innate immune deficiency of human neonates. Blood 2009; 113(25):6419-6427.
259. Ishii S, Nagase T, Tashiro F, et al. Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. EMBO J 1997; 16(1):133-142.
260. Wang H, Tan X, Chang H, et al. Regulation of platelet-activating factor receptor gene expression in vivo by endotoxin, platelet-activating factor and endogenous tumour necrosis factor. Biochem J 1997; 322(Pt 2):603-608.
261. Rabinovici R, Esser KM, Lysko PG, et al. Priming by platelet-activating factor of endotoxininduced lung injury and cardiovascular shock. Circ Res 1991; 69(1):12-25.
262. Chang SW. Endotoxin-induced lung vascular injury: role of platelet activating factor, tumor necrosis factor and neutrophils. Clin Res 1992; 40(3):528-536.
263. Chang SW, Feddersen CO, et al. Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J Clin Invest 1987; 79(5):1498-1509.
264. Miotla JM, Jeffery PK, Hellewell PG. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am J Respir Cell Mol Biol 1998; 18(2):197-204.
265. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998; 101(7):1458-1467.
266. Kim JD, Baker CJ, Roberts RF, et al. Platelet activating factor acetylhydrolase decreases lung reperfusion injury. Ann Thorac Surg 2000; 70(2):423-428.
267. Göggel R, Winoto-Morbach S, Vielhaber G, et al. PAF-mediated pulmonary edema: a new role for acid sphingomyelinase and ceramide. Nat Med 2004; 10(2):155-160.
268. Zimmerman GA, McIntyre TM. PAF, ceramide and pulmonary edema: alveolar flooding and a flood of questions. Trends Mol Med 2004; 10(6):245-248.
269. Dhainaut JF, Tenaillon A, Le Tulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22(11):1720-1728.
270. Dhainaut JF, Tenaillon A, Hemmer M, et al. Confirmatory platelet-activating factor receptor antagonist trial in patientswith severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group. Crit Care Med 1998; 26(12):1963-1971.
271. Poeze M, Froon AH, Ramsay G, et al. Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II trial. TCV-309 Septic Shock Study Group. Shock 2000; 14(4):421-428.
272. Vincent JL, Spapen H, Bakker J, et al. Phase II multicenter clinical study of the plateletactivating factor receptor antagonist BB-882 in the treatment of sepsis. Crit Care Med 2000; 28(3):638-642.
273. Gomes RN, Bozza FA, et al. Exogenous platelet-activating factor acetylhydrolase reduces mortality in mice with systemic inflammatory response syndrome and sepsis. Shock 2006; 26(1):41-49.
274. Schuster DP, MetzlerM, Opal S, et al. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31(6):1612-1619.
275. Opal S, Laterre PF, Abraham E, et al. Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32(2):332-341.
276. Minneci PC, Deans KJ, et al. Should we continue to target the platelet-activating factor pathway in septic patients? Crit Care Med 2004; 32(2):585-588.
277. Zimmerman GA. Plasma platelet-activating factor acetylhydrolase is a dynamic variable in critical illness: In the end, is change good for you? Crit Care Med 2005; 33(6):1462-1463.
278. Claus RA, Russwurm S, et al. Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med 2005; 33(6):1416-1419.
279. Grissom CK, Orme JF Jr, et al. Platelet-activating factor acetylhydrolase is increased in lung lavage fluid from patients with acute respiratory distress syndrome. Crit Care Med 2003; 31(3):770-775.
280. Salluh JI, Pino AV, Silva AR, et al. Lung production of platelet-activating factor acetylhydrolase in oleic acid-induced acute lung injury. Prostaglandins Leukot Essent Fatty Acids 2007; 77(1):1-8.
281. Eichacker PQ, Parent C, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166(9):1197-1205.
282. Hoffmann JA, Kafatos FC, et al. Phylogenetic perspectives in innate immunity. Science 1999; 284(5418):1313-1318.
283. Munford RS, Pugin J. The crucial role of systemic responses in the innate (non-adaptive) host defense. J Endotoxin Res 2001; 7(4):327-332.
284. Scherfer C, Karlsson C, et al. Isolation and characterization of hemolymph clotting factors in Drosophila melanogaster by a pullout method. Curr Biol 2004; 14(7):625-629.
285. Kambris Z, Brun S, et al. Drosophila immunity: a large-scale in vivo RNAi screen identifies five serine proteases required for Toll activation. Curr Biol 2006; 16(8):808-813.
286. Amaral A, Opal SM, Vincent JL. Coagulation in sepsis. Intensive Care Med 2004; 30(6): 1032-1040.
287. Diehl JL, Borgel D. Sepsis and coagulation. Curr Opin Crit Care 2005; 11(5):454-460.
288. MackmanN, Tilley RE, et al. Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis. Arterioscler Thromb Vasc Biol 2007; 27(8):1687-1693.
289. Panes O, Matus V, et al. Human platelets synthesize and express functional tissue factor. Blood 2007; 109(12):5242-5250.
290. Lorant D, McIntyre T, et al. Platelet-activating factor: a signaling molecule for leukocyte adhesion. In: Pearson JD, ed. Vascular Adhesion Molecules and Inflammation. Basel: Birkhauser, 1999:81-107.
291. Lindemann S, Tolley ND, DixonDA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol 2001; 154(3):485-490.
292. Bernard GR, Vincent JL, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10):699-709.
293. Li W, Zheng X, Gu J, et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005; 3(7):1351-1359.
294. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001; 29(7 Suppl):S48-S51; discussion 51-52.
295. Stephenson, DA, Toltl LJ, et al. Modulation of monocyte function by activated protein C, a natural anticoagulant. J Immunol 2006; 177(4):2115-2122.
296. Hoffmann JN, Vollmar B, Laschke MW, et al. Microhemodynamic and cellular mechanisms of activated protein C action during endotoxemia. Crit Care Med 2004; 32(4):1011-1017.
297. Nick JA, Coldren CD, Geraci MW, et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 2004; 104(13):3878-3885.
298. Lay AJ, Donahue D, et al. Acute inflammation is exacerbated in mice genetically predisposed to a severe protein C deficiency. Blood 2007; 109(5):1984-1991.
299. Kerschen EJ, Fernandez JA, Cooley BC, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204(10):2439-2448.
300. Neyrinck AP, Liu KD, Howard JP, et al. Protective mechanisms of activated protein C in severe inflammatory disorders. British Journal of Pharmacology 2009, in press.
301. Looney MR, Matthay MA. Bench-to-bedside review: the role of activated protein C in maintaining endothelial tight junction function and its relationship to organ injury. Crit Care 2006; 10(6):239.
302. Ruf W. Protease-activated receptor signaling in the regulation of inflammation. Crit Care Med 2004; 32(5 Suppl):S287-S292.
303. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 2005; 105(8):3178-3184.
304. Finigan JH, Dudek SM, Singleton PA, et al. Activated protein Cmediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005; 280(17):17286-17293.
305. Ware LB, Matthay MA. Measuring microvascular blood flow in sepsis-a continuing challenge. Lancet 2002; 360(9341):1187-1188.
306. Richardson MA, Gupta A, et al. Treatment of sepsis-induced acquired protein C deficiency reverses Angiotensin-converting enzyme-2 inhibition and decreases pulmonary inflammatory response. J Pharmacol Exp Ther 2008; 325(1):17-26.
307. Faust SN, Levin M, Harrison OB, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345(6):408-416.
308. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22(4):401-404.
309. Idell S. Anticoagulants for acute respiratory distress syndrome: can they work? Am J Respir Crit Care Med 2001; 164(4):517-520.
310. Abraham E. Coagulation abnormalities in acute lung injury and sepsis. Am J Respir Cell Mol Biol 2000; 22(4):401-404.
311. Welty-Wolf KE, Carraway MS, et al. Antibody to intercellular adhesion molecule 1 (CD54) decreases survival and not lung injury in baboons with sepsis. Am J Respir Crit Care Med 2001; 163(3, pt 1):665-673.
312. Welty-Wolf KE, Carraway MS, Ortel TL, et al. Blockade of tissue factor-factor X binding attenuates sepsis-induced respiratory and renal failure. Am J Physiol Lung Cell Mol Physiol 2006; 290(1):L21-L31.
313. Fan J, Kapus A, et al. Priming for enhanced alveolar fibrin deposition after hemorrhagic shock: role of tumor necrosis factor. Am J Respir Cell Mol Biol 2000; 22(4):412-421.
314. Fan J, Li Y, et al. Hemorrhagic shock-activated neutrophils augment TLR4 signaling-induced TLR2 upregulation in alveolar macrophages: role in hemorrhage-primed lung inflammation. Am J Physiol Lung Cell Mol Physiol 2006; 290(4):L738-L746.
315. Matthay MA, Zimmerman GA, et al. Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 2003; 167(7):1027-1035.
316. Bachofen M, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977; 116(4):589-615.
317. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982; 3(1):35-56.
318. McFeely JE, Hudson LD. Sepsis, multi-organ dysfunction syndrome, and adult respiratory distress syndrome in humans. In: Brigham KL, ed. Endotoxin and the Lungs. New York: Marcel Dekker, Inc., 1994:321-350.
319. Brun-Buisson C, Doyon F, et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995; 274(12):968-974.
320. Fein AM, Lippmann M, et al. The risk factors, incidence, and prognosis of ARDS following septicemia. Chest 1983; 83(1):40-42.
321. Nuckton TJ, Alonso JA, et al. Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 2002; 346(17):1281-1286.
322. Powe JE, Short A, et al. Pulmonary accumulation of polymorphonuclear leukocytes in the adult respiratory distress syndrome. Crit Care Med 1982; 10(11):712-718.
323. Elliott CG, Zimmerman GA, et al. Granulocyte aggregation in adult respiratory distress syndrome (ARDS)-serial histologic and physiologic observations. Am J Med Sci 1985; 289(2):70-74.
324. Warshawski FJ, Sibbald WJ, et al. Abnormal neutrophil-pulmonary interaction in the adult respiratory distress syndrome. Qualitative and quantitative assessment of pulmonary neutrophil kinetics in humans with in vivo 111indium neutrophil scintigraphy. Am Rev Respir Dis 1986; 133(5):797-804.
325. Zimmerman GA, Renzetti AD, et al. Granulocyte adherence in pulmonary and systemic arterial blood samples from patients with adult respiratory distress syndrome. Am Rev Respir Dis 1984; 129(5):798-804.
326. Schuster DP. The opportunities and challenges of developing imaging biomarkers to study lung function and disease. Am J Respir Crit Care Med 2007; 176(3):224-230.
327. Rodrigues RS, Miller PR, Bozza FA, et al. FDG-PET in patients at risk for acute respiratory distress syndrome: a preliminary report. Intensive Care Med 2008; 34(12):2273-2278.
328. AlbertineK. Histopathology of pulmonary edema and the acute respiratory distress syndrome. In: Matthay M, Ingbar DH, eds. Pulmonary Edema. New York: Marcel Dekker, Inc., 1998: 37-83.
329. Imaizumi T, Albertine KH, et al. Human endothelial cells synthesize ENA-78: relationship to IL-8 and to signaling of PMN adhesion. Am J Respir Cell Mol Biol 1997; 17(2):181-192.
330. Dalldorf FG, Carney CN, et al. Pulmonary capillary thrombosis in septicemia due to grampositive bacteria. JAMA 1968; 206(3):583-586.
331. Tomashefski JF. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000; 21(3):435-466.
332. Parsons PE, Gillespie MM, et al. Neutrophil response to endotoxin in the adult respiratory distress syndrome: role of CD14. Am J Respir Cell Mol Biol 1995; 13(2):152-160.
333. Doerschuk CM Mechanisms of leukocyte sequestration in inflamed lungs. Microcirculation 2001; 8(2):71-88.
334. Steinberg KP, Milberg JA, et al. Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome. Am J Respir Crit Care Med 1994; 150(1):113-122.
335. Rosseau S, Hammerl P, et al. Phenotypic characterization of alveolar monocyte recruitment in acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2000; 279(1):L25-L35.
336. Mendez JL, Hubmayr RD. New insights into the pathology of acute respiratory failure. Curr Opin Crit Care 2005; 11(1):29-36.
337. Coalson JJ, Hinshaw LB, et al. The pulmonary ultrastructure in septic shock. Exp Mol Pathol 1970; 12(1):84-103.
338. Dormehl IC, Maree M, et al. Investigation by scintigraphic methods of neutrophil kinetics under normal and septic shock conditions in the experimental baboon model. Eur J Nucl Med 1990; 16(8-10):643-647.
339. Albertine KH, Soulier MF, Wang Z, et al. Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome. Am J Pathol 2002; 161(5):1783-1796.
340. Gupta N, Su X, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007; 179(3):1855-1863.
341. Zapol WM, Jones R. Vascular components of ARDS. Clinical pulmonary hemodynamics and morphology. Am Rev Respir Dis 1987; 136(2):471-474.
342. Bertozzi P, Astedt B, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322(13):890-897.
343. Wang L, Bastarache JA, et al. Novel role of the human alveolar epithelium in regulating intra-alveolar coagulation. Am J Respir Cell Mol Biol 2007; 36(4):497-503.
344. Ware LB, Fang X, et al. Protein C and thrombomodulin in human acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285(3):L514-L521.
345. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005; 353(13):1332-1341.
346. Parsons PE. Mediators andmechanisms of acute lung injury. Clin ChestMed 2000; 21(3):467-476.
347. Ware LB, Conner ER, et al. von Willebrand factor antigen is an independent marker of poor outcome in patients with early acute lung injury. Crit Care Med 2001; 29(12):2325-2331.
348. Harbarth S, Holeckova K, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164(3):396-402.
349. Claeys R, Vinken S, et al. Plasma procalcitonin and C-reactive protein in acute septic shock: clinical and biological correlates. Crit Care Med 2002; 30(4):757-762.
350. Pettila V. How successful is the intensive care of patients with multiple organ dysfunction?]. Duodecim 2002; 118(16):1663-1670.
351. Reinhart K, Bayer O, et al. Markers of endothelial damage in organ dysfunction and sepsis. Crit Care Med 2002; 30(Suppl. 5):S302-S312.
352. Bajwa EK, Boyce PD, et al. Biomarker evidence of myocardial cell injury is associated with mortality in acute respiratory distress syndrome. Crit Care Med 2007; 35(11):2484-2490.
353. Nobre V, Harbarth S, Graf JD, et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit CareMed 2008; 177(5):498-505.
354. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol 2004; 172(5):2731-2738.
355. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8(9):942-949.
356. Mizgerd JP, Skerrett SJ. Animal models of human pneumonia. Am J Physiol Lung Cell Mol Physiol 2008; 294(3):L387-L398.
357. Lowry SF. Human endotoxemia: a model for mechanistic insight and therapeutic targeting. Shock 2005; 24(Suppl. 1):94-100.